MY131949A - Vaccines - Google Patents

Vaccines

Info

Publication number
MY131949A
MY131949A MYPI20023515A MYPI20023515A MY131949A MY 131949 A MY131949 A MY 131949A MY PI20023515 A MYPI20023515 A MY PI20023515A MY PI20023515 A MYPI20023515 A MY PI20023515A MY 131949 A MY131949 A MY 131949A
Authority
MY
Malaysia
Prior art keywords
fragment
epitope
hiv
gag
encodes
Prior art date
Application number
MYPI20023515A
Other languages
English (en)
Inventor
Andrew Beaton
Peter Franz Ertl
Gerald Wayne Gough
Andrew Lear
John Philip Tite
Catherine Ann Van Wely
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY131949A publication Critical patent/MY131949A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI20023515A 2001-09-20 2002-09-20 Vaccines MY131949A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines

Publications (1)

Publication Number Publication Date
MY131949A true MY131949A (en) 2007-09-28

Family

ID=43927344

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20023515A MY131949A (en) 2001-09-20 2002-09-20 Vaccines

Country Status (6)

Country Link
KR (1) KR101067231B1 (de)
AT (1) ATE506439T1 (de)
DE (1) DE60239815D1 (de)
MY (1) MY131949A (de)
TW (1) TWI329647B (de)
ZA (1) ZA200402189B (de)

Also Published As

Publication number Publication date
TWI329647B (en) 2010-09-01
ATE506439T1 (de) 2011-05-15
DE60239815D1 (de) 2011-06-01
ZA200402189B (en) 2005-07-27
KR20040039387A (ko) 2004-05-10
HK1066830A1 (en) 2005-04-01
KR101067231B1 (ko) 2011-09-22

Similar Documents

Publication Publication Date Title
WO2003025003A3 (en) Hiv-gag codon-optimised dna vaccines
MY145614A (en) Vaccine
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
CY1106635T1 (el) Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια
MXPA05010007A (es) Replicones de alfavirus y construcciones auxiliares mejorados.
WO2003092600A3 (en) Site specific listeria integration vectors and methods for using the same
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
DE69941049D1 (de) Retrovirales verabreichungssystem
EA200700904A1 (ru) Вакцины против вируса японского энцефалита и вируса западного нила
WO2000029561A3 (en) Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
ZA200107072B (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
TW200502245A (en) Vaccine
MY131949A (en) Vaccines
PT831899E (pt) Composições de poxvírus-calicivírus recombinantes e suas utilizações
WO2002022663A3 (en) Stress resistant retroviruses
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2003089571A3 (en) Ehrlichia canis genes and vaccines
WO2003052122A3 (en) Gp41 inhibitor
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
DE60235223D1 (de) Streptococcus pyogenes polypeptide und entsprechende dna fragmente
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
WO2001007625A3 (en) Ehrlichia canis genes and vaccines